Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.35 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.31 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.31 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675968 | 0.83 | AURKA (0.32) | ANO1GSK3BCDK1CDK2AURKA | |
| SCHEMBL16675894 | 0.78 | RAB9A (0.39) | CYP2D6CDK2GRM4AURKAAURKB | |
| SCHEMBL18556885 | 0.76 | CYP2D6 (0.49) | CYP2D6GRM4RAPGEF3RAPGEF4 | |
| SCHEMBL16675939 | 0.71 | CDK2 (0.39) | CYP2D6GSK3BCDK1CDK2GRM4 | |
| SCHEMBL16752855 | 0.69 | CHRNA1 (0.34) | ANO1CDK2 | |
| SCHEMBL16752857 | 0.69 | CHRNA1 (0.34) | ANO1CDK2 | |
| SCHEMBL18159978 | 0.67 | CYP2D6 (0.39) | CYP2D6GRM4RAPGEF3RAPGEF4 | |
| SCHEMBL21093187 | 0.66 | CYP2D6 (0.50) | CYP2D6GRM4 | |
| SCHEMBL16675943 | 0.66 | GRM4 (0.40) | CYP2D6GSK3BGRM4AURKACYP1A2 | |
| SCHEMBL16797226 | 0.66 | CYP2D6 (0.42) | CYP2D6GRM4RAPGEF3RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | CYP2D6 3177/4885P2RX1 1487/4885P2RX4 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.